Quick summary
Deltorphin is a family of frog-skin heptapeptides with exceptional delta-opioid receptor selectivity, potentially offering analgesia with less respiratory depression and dependence than classical opioids.
Overview
Deltorphin is a family of heptapeptides isolated from the skin of South American Phyllomedusa frogs. These opioid peptides show exceptional selectivity for delta-opioid receptors, with affinity several orders of magnitude greater than for mu-opioid receptors, making them invaluable research tools for studying pain modulation and opioid receptor pharmacology.
Mechanism of action
Deltorphins bind with high selectivity to delta-opioid receptors (DOR), acting as potent agonists. Activation of DOR inhibits adenylyl cyclase via Gi/Go proteins, reduces neuronal excitability, and modulates neurotransmitter release. Unlike mu-opioid receptor agonists, delta-selective compounds may produce analgesia with reduced respiratory depression, tolerance, and physical dependence, making them subjects of interest for analgesic drug development.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| receptor binding research | intravenous | 1–10 mcg/kg | single dose per experiment |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Preclinical studies confirm Deltorphin's role as a delta-opioid receptor agonist with nanomolar affinity. Research has explored its analgesic, cardioprotective, and neuroprotective properties in rodent models. Deltorphin II has been used extensively to characterize DOR pharmacology. No human clinical trials have been conducted due to its research-only status.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Deltorphin for synergistic effects.
Legal status
Deltorphins are not approved for human use and are available for research purposes only. They are not scheduled substances in most jurisdictions but require appropriate laboratory handling protocols.
Sourcing & access
Research compound
Deltorphin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Deltorphin is a family of heptapeptides isolated from the skin of South American Phyllomedusa frogs. These opioid peptides show exceptional selectivity for delta-opioid receptors (DOR), with affinity several orders of magnitude greater than for mu-opioid receptors, making them invaluable research tools for studying opioid receptor pharmacology.
Deltorphins bind with high selectivity to delta-opioid receptors, acting as potent agonists. DOR activation inhibits adenylyl cyclase via Gi/Go proteins, reduces neuronal excitability, and modulates neurotransmitter release. Unlike mu-opioid agonists, delta-selective compounds may produce analgesia with reduced respiratory depression and tolerance.
Deltorphins are research compounds not approved for human use. In animal models, reported effects include sedation, reduced locomotion, and respiratory effects at high doses. Their delta-receptor selectivity suggests a potentially safer analgesic profile than mu-opioid agonists, but no human clinical trials have been conducted.
Deltorphin II has been used extensively to characterize DOR pharmacology. Delta-opioid receptor agonists may produce pain relief with reduced respiratory depression, tolerance, and physical dependence compared to mu-opioid drugs, making delta-selective analgesics a promising research direction for safer pain management.